IL-13Rα2 is significantly upregulated in a number of human cancers [22–24] and has been successfully applied as therapeutic target of chimeric antigen receptor (CAR)-engineered T cells in a patient with recurrent multifocal glioblastoma [25]. Here, IL13RA2 is linked to cancer.